Document is current
Any future updates will be listed below
-
Authors
Pinto-Sanchez, M. Ines https://orcid.org/0000-0002-9040-9824
Silvester, Jocelyn A.
Lebwohl, Benjamin
Leffler, Daniel A.
Anderson, Robert P. https://orcid.org/0000-0002-0764-7267
Therrien, Amelie
Kelly, Ciaran P.
Verdu, Elena F. https://orcid.org/0000-0001-6346-2665
- License Information
-
More Information
Article History
Accepted: 4 August 2021
First Online: 15 September 2021
Competing interests
: B.L. has consulted for Takeda and Anokion. D.A.L. receives salary support from Takeda Pharmaceuticals unrelated to this manuscript. M.I.P.-S. has consulted for Takeda and Lupin unrelated to this manuscript. J.A.S. has consulted for Takeda Pharmaceuticals and received grant funding from Glutenostics, Milky Way Life Sciences, the Celiac Disease Foundation and BEYOND Celiac. E.F.V. received grant funding from Biocodex Foundation and Gilead unrelated to this manuscript. R.P.A. has served as consultant for Takeda, GSK, Anokion, Allero Therapeutics, TregTherapeutics and EVOQ Therapeutics. R.P.A. is founder and shareholder of Novoviah Pharmaceuticals and is the inventor of patents relating to the diagnosis and treatment of coeliac disease. The remaining authors declare no competing interests.
